Ira Shoulson

TL;DR: The clinical data suggest that levodopa either slows the progression of Parkinson's disease or has a prolonged effect on the symptoms of the disease, and the neuroimaging data suggest either thatlevodopa accelerates the loss of nigrostriatal dopamine nerve terminals or that its pharmacologic effects modify the dopamine transporter.

TL;DR: At an early stage of the disease, subjects with Huntington’s disease had lower body mass index than matched controls from the general population and the parallel to observations in transgenic mouse models suggests that it is a significant hallmark of Huntington's disease gene expression.

TL;DR: Coenzyme Q10 was safe and well tolerated in this population, but showed no evidence of clinical benefit, and the study was terminated after a prespecified futility criterion was reached.

TL;DR: Inosine was generally safe, tolerable, and effective in raising serum and cerebrospinal fluid urate levels in early PD and support advancing to more definitive development of inosine as a potential disease-modifying therapy for PD.

TL;DR: This work uses smoking and cancer screening data to test the corollary that health capital responds to life expectancy, and compares investments for individuals who have ex-ante identical risks of HD but differ in disease realization.